Loading organizations...
Kinnos is a technology company.
Kinnos provides visible disinfection technology, offering products that improve the efficacy of infection prevention protocols. Their flagship product, Highlight, is a color additive designed to be mixed with existing disinfectants, visually confirming coverage on surfaces. This unique approach transforms a typically invisible process into a clear indication of thorough disinfection, enhancing safety and compliance in critical environments.
The company was co-founded in 2014 by Jason Kang, Katherine Jin, and Kevin Tyan while they were students at Columbia University. Their founding insight stemmed from observing challenges in infection control, particularly during public health crises, where the lack of immediate feedback on disinfectant application created risks. This led them to develop a practical solution that ensures proper surface treatment.
Kinnos targets institutions and facilities prioritizing stringent infection prevention, including healthcare settings and other environments where effective sanitization is paramount. The company's vision centers on establishing a new standard for disinfection practices, empowering individuals and organizations with enhanced visibility and confidence in their efforts to protect against pathogens and safeguard community health.
Kinnos has raised $22.0M across 3 funding rounds.
Kinnos has raised $22.0M in total across 3 funding rounds.
Kinnos is a healthcare technology company that makes disinfecting easier and more reliable by adding a temporary color indicator to existing disinfectants and wipes so users can *see* coverage and proper technique in real time[5].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech & Health Landscape
Quick Take & Future Outlook
Quick take: Kinnos took a simple, human‑centered insight—make disinfecting visible—and turned it into a commercially viable, defensible product that reduces reliance on training alone to achieve proper cleaning; the company’s challenge going forward will be proving consistent clinical outcomes at scale and embedding Highlight into institutional purchasing and standards so the behavior change becomes routine[1][5][3].
Kinnos has raised $22.0M in total across 3 funding rounds.
Kinnos's investors include Kapor Center, Partnership Fund for New York City, Pioneer Healthcare Partners, Robert Rosenberg, NextGen Venture Partners, Grace Beauty Capital, Mark Chou, Ozzy Akay, Allston Venture Fund, Golden Seeds, MEDA Angels, Georgica Advisors.
Kinnos has raised $22.0M across 3 funding rounds. Most recently, it raised $15.0M Other Equity in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 2, 2023 | $15.0M Other Equity | Kapor Center, Partnership Fund for New York City, Pioneer Healthcare Partners | |
| Feb 1, 2020 | $6.0M Series A | Robert Rosenberg | NextGen Venture Partners, Grace Beauty Capital, Mark Chou, Ozzy Akay, Allston Venture Fund, Golden Seeds, MEDA Angels, Partnership Fund for New York City |
| Mar 8, 2017 | $1.0M Seed | Georgica Advisors | New York Angels, VentureWell |